文献詳細
特集 腎移植臨床の進歩―集学的治療における泌尿器科医の役割を再考する
〈免疫抑制〉
文献概要
▶ポイント
・腎移植医療において,抗体関連拒絶反応の制御および加療は非常に重要である.
・特に抗ドナー特異抗体に関して,既存抗体に対しては移植前の減感作療法が,移植後は新規抗体産生の抑止を目的とした免疫抑制療法が必要とされる.
・抗体関連拒絶反応は治療抵抗性であり,依然確立された治療はない.
・腎移植医療において,抗体関連拒絶反応の制御および加療は非常に重要である.
・特に抗ドナー特異抗体に関して,既存抗体に対しては移植前の減感作療法が,移植後は新規抗体産生の抑止を目的とした免疫抑制療法が必要とされる.
・抗体関連拒絶反応は治療抵抗性であり,依然確立された治療はない.
参考文献
1) Aubert O, Loupy A, Hidalgo L, et al : Antibody-Mediated Rejection Due to Preexisting versus De Novo Donor-Specific Antibodies in Kidney Allograft Recipients. J Am Soc Nephrol 28 : 1912-1923, 2017
2) 日本移植学会臓器移植抗体陽性診療ガイドライン策定委員会 (編) : 臓器移植抗体陽性診療ガイドライン2018年版. メディカルレビュー社, 東京, 2018
3) Montgomery RA, Loupy A and Segev DL : Antibody-mediated rejection : New approaches in prevention and management. Am J Transplant 18 (Suppl 3) : 3-17, 2018
4) Dunn TB, Noreen H, Gillingham K, et al : Revisiting traditional risk factors for rejection and graft loss after kidney transplantation. Am J Transplant 11 : 2132-2143, 2011
5) Konvalinka A and Tinckam K : Utility of HLA Antibody Testing in Kidney Transplantation. J Am Soc Nephrol 26 : 1489-1502, 2015
6) Wiebe C, Gibson IW, Blydt-Hansen TD, et al : Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody. Am J Transplant 15 : 2921-2930, 2015
7) Ishida H, Furusawa M, Shimizu T, et al : Influence of preoperative anti-HLA antibodies on short- and long-term graft survival in recipients with or without rituximab treatment. Transpl Int 27 : 371-382, 2014
8) Unagami K, Ishida H, Furusawa M, et al : Influence of Low Dose-based Tacrolimus Protocol on the Appearance Rate of de novo Donor Specific Antibodies during Seven Years Follow-up after Renal Transplantation. [Under Submission]
9) Marfo K, Ajaimy M, Colovai A, et al : Pretransplant immunologic risk assessment of kidney transplant recipients with donor-specific anti-human leukocyte antigen antibodies. Transplantation 98 : 1082-1088, 2014
10) Chehade H and Pascual M : The Challenge of Acute Antibody-Mediated Rejection in Kidney Transplantation. Transplantation 100 : 264-265, 2016
11) Okada D, Okumi M, Kakuta Y, et al : Outcome of the risk-stratified desensitization protocol in donor-specific antibody-positive living kidney transplant recipients : a retrospective study. Transpl Int, 2018 [Epub ahead of print]
12) Glotz D, Russ G, Rostaing L, et al : Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies. Am J Transplant, 2019 [Epub ahead of print]
13) Rodrigo E, Segundo DS, Fernández-Fresnedo G, et al : Within-Patient Variability in Tacrolimus Blood Levels Predicts Kidney Graft Loss and Donor-Specific Antibody Development. Transplantation 100 : 2479-2485, 2016
14) Davis S, Gralla J, Klem P, et al : Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation. Am J Transplant 18 : 907-915, 2018
15) Wiebe C, Rush DN, Nevins TE, et al : Class II Eplet Mismatch Modulates Tacrolimus Trough Levels Required to Prevent Donor-Specific Antibody Development. J Am Soc Nephrol 28 : 3353-3362, 2017
16) Wan SS, Ying TD, Wyburn K, et al : The Treatment of Antibody-Mediated Rejection in Kidney Transplantation : An Updated Systematic Review and Meta-Analysis. Transplantation 102 : 557-568, 2018
17) Moreso F, Crespo M, Ruiz JC, et al : Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab : A multicenter, prospective, randomized, double-blind clinical trial. Am J Transplant 18 : 927-935, 2018
18) Velidedeoglu E, Cavaillé-Coll MW, Bala S,et al : Summary of 2017 FDA Public Workshop : Antibody-mediated Rejection in Kidney Transplantation. Transplantation 102 : e257-e264, 2018
掲載誌情報